The Oncology Institute (TOI) Insider Chernett Buys $90K of Stock

Jorey Chernett recently purchased 18,000 shares of The Oncology Institute, Inc. (NasdaqCM: TOI) on June 23, 2026. The shares were acquired at an average price of $5.02 each, amounting to a total transaction value of $90,360. This move adds to Chernett's existing stake in the company, reflecting continued confidence in the oncology service provider.

Insider Buying and Selling at The Oncology Institute, Inc.

Jorey Chernett, along with other insiders, has been actively trading shares of The Oncology Institute. On June 23, 2026, Chernett bought 18,000 shares at $5.02 each. Earlier, on June 4, Chernett acquired 12,000 shares at $4.75 per share. Meanwhile, Chief Medical Officer Yale Podnos sold 23,451 shares at $5.38 on June 8, 2026, as part of a planned sale. CEO Daniel Virnich and CFO Robert Ross also sold shares on May 21, 2026, at a price of $4.47 each.

Other Institutional Activity in The Oncology Institute

Several institutional investors have adjusted their holdings in The Oncology Institute. BlackRock, Inc. increased its holdings by 510,534 shares, reaching a total of 4,415,867 shares valued at approximately $13.6 million, marking a 13.1% increase. Vanguard Capital Management LLC opened a new position with 3,476,781 shares worth about $10.7 million. Deerfield Management Company, L.P. maintained its position with 3,360,052 shares valued at $10.3 million. Conversely, Kanen Wealth Management LLC reduced its stake by 198,286 shares, now holding 2,777,858 shares worth $8.5 million, a 6.7% decrease.

The Oncology Institute, Inc. Stock Snapshot

Shares of The Oncology Institute, Inc. traded near $5.30 on Wednesday. The company, with a market cap of approximately $500.9 million, operates in the healthcare sector, specifically in medical care facilities. It has a forward P/E ratio that isn't meaningful due to negative earnings and a beta of 0.406, indicating lower volatility. The stock's 52-week range is between $2.02 and $5.58, with a 50-day moving average of $4.16 and a 200-day moving average of $3.57.

Analysts Set New Price Targets

Analysts have been positive about The Oncology Institute's prospects. On June 17, 2026, Needham maintained its 'buy' rating with a target price of $7.00. Earlier in June, BTIG also maintained a 'buy' rating, setting an $8.00 price target. The consensus among analysts is a strong buy, with a mean price target of $7.75 based on four opinions.

About The Oncology Institute, Inc.

The Oncology Institute, Inc. provides a range of oncology services in the U.S., including physician services, in-house infusion, and specialty pharmacy services. It operates through segments like Specialty Pharmacy, Patient Services, and Clinical Trials & Other. Headquartered in Cerritos, California, the company is led by CEO Dr. Daniel Virnich and employs 641 people.

Bottom Line

Jorey Chernett's recent purchase of shares in The Oncology Institute, Inc. suggests a positive outlook for the company. The stock's activity, coupled with analyst endorsements, indicates interest from both insiders and institutions. Investors should note that insider transactions are disclosed after the fact and may not reflect the current sentiment.